Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Stock Rated “Moderate Buy” by Wall Street Brokerages

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has earned an average rating of “Moderate Buy” from the twelve ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $56.38.

Several research analysts have issued reports on IMCR shares. Zacks Research cut Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 3rd. JPMorgan Chase & Co. assumed coverage on Immunocore in a research note on Friday, August 21st. They set an “overweight” rating and a $50.00 price target for the company. Wall Street Zen lowered shares of Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Thursday. Finally, Mizuho increased their price objective on shares of Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd.

Institutional Trading of Immunocore

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMCR. Hennion & Walsh Asset Management Inc. raised its position in Immunocore by 2.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,324 shares of the company’s stock worth $1,534,000 after acquiring an additional 1,197 shares during the period. GAMMA Investing LLC grew its position in shares of Immunocore by 202.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock valued at $61,000 after acquiring an additional 1,286 shares during the period. Rockefeller Capital Management L.P. bought a new stake in shares of Immunocore during the 4th quarter valued at $47,000. Royal Bank of Canada increased its stake in shares of Immunocore by 5.2% in the 1st quarter. Royal Bank of Canada now owns 44,714 shares of the company’s stock worth $1,348,000 after purchasing an additional 2,228 shares in the last quarter. Finally, Public Employees Retirement System of Ohio increased its stake in shares of Immunocore by 24.2% in the 1st quarter. Public Employees Retirement System of Ohio now owns 31,253 shares of the company’s stock worth $942,000 after purchasing an additional 6,090 shares in the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Stock Performance

Shares of NASDAQ IMCR traded down $0.08 during midday trading on Friday, hitting $29.40. 924,922 shares of the stock traded hands, compared to its average volume of 456,921. The firm has a 50-day moving average of $33.09 and a two-hundred day moving average of $31.62. The firm has a market capitalization of $1.51 billion, a P/E ratio of -79.46 and a beta of 0.81. The company has a debt-to-equity ratio of 0.94, a quick ratio of 4.44 and a current ratio of 4.47. Immunocore has a one year low of $27.50 and a one year high of $40.71.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. On average, equities analysts forecast that Immunocore will post 0.06 EPS for the current fiscal year.

About Immunocore

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapies designed to treat cancer and other serious diseases. Its ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and redirect the patient’s T cells to destroy those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is a bispecific TCR therapy approved in the United States and Europe for certain adults with unresectable or metastatic uveal melanoma, a rare form of eye cancer.